Oxford Gene Technology has named Bob Holland as its new chief medical officer.
Holland previously was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division, which he helped create.
In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.
Former US Vice President Dan Quayle has been elected to the TGen Foundation's board of directors.
The foundation is the fundraising branch of the Translational Genomics Research Institute.
Quayle is chairman of the private equity firm Cerberus Global Investments. He is a resident of Paradise Valley, Ariz., and he grew up in Phoenix.